NCT06848088
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Enrolling by Invitation
PHASE2Ages 18+InterventionalRegeneron Pharmaceuticals
~48 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Fianlimab+cemiplimab
At a glance
Recruiting sites
0 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613
Measured over Up to 4 years
Conditions
Where it's being run
11 sites across 9 statesCalifornia2
Michigan2
Colorado1
Kansas1
New Jersey1
Tennessee1
Texas1
Virginia1
Study leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613Up to 4 years